NEW YORK, December 29, 2025 — SELLAS Life Sciences Group has provided a key update on its pivotal Phase 3 REGAL clinical trial evaluating galinpepimut-S (GPS) as a maintenance immunotherapy for patients with acute myeloid leukemia (AML) who have achieved a second complete remission. The company confirmed that 72 survival events have occurred toward the 80 events required to trigger the final overall survival analysis, while remaining fully blinded to efficacy outcomes. The trial continues without modification following prior Independent Data Monitoring Committee review, reinforcing the integrity of this late-stage study.
Science Significance
Scientifically, the REGAL trial represents an important evaluation of targeted cancer immunotherapy in a high-risk AML population. Galinpepimut-S is designed to target WT1 (Wilms Tumor 1), a protein overexpressed in multiple leukemias and solid tumors and associated with poor prognosis. By stimulating an immune response against WT1-expressing cells, GPS aims to extend remission duration and improve survival after second-line therapy, a setting where disease relapse is common. The event-driven nature of the trial, with overall survival as the primary endpoint, underscores the scientific rigor required to demonstrate meaningful benefit in AML.
Regulatory Significance
From a regulatory perspective, the REGAL study is a registrational Phase 3 trial, positioning GPS as a potential candidate for future regulatory submission if results are positive. Confirmation that the study continues without protocol changes following IDMC review supports regulatory confidence in trial conduct, safety oversight, and statistical integrity. The fact that SELLAS remains blinded and that no interim statistical penalties have been incurred preserves the robustness of the final analysis, a critical factor for regulators assessing late-stage oncology data packages.
Business Significance
Advertisement
For SELLAS, the update carries significant strategic and commercial implications. As a late-stage biopharmaceutical company, the REGAL trial represents a value-defining program. Progress toward the final analysis milestone increases visibility among investors, partners, and oncology stakeholders, particularly as longer-than-expected survival trends may enhance the perceived probability of success. A positive outcome could materially expand the company’s oncology franchise and complement its broader pipeline, strengthening SELLAS’ position within the competitive cancer immunotherapy market.
Patients’ Significance
For patients with AML, particularly those who are unable to undergo stem cell transplantation after relapse, treatment options remain limited and outcomes are poor. Current standard approaches following second remission often yield median overall survival of less than one year. The REGAL trial addresses this unmet need by evaluating a potentially less toxic, immune-based maintenance therapy designed to prolong survival. While definitive results are pending, continued trial progression offers measured optimism for patients and caregivers seeking more durable disease control.
Policy Significance
At a policy level, the REGAL trial highlights the importance of supporting late-stage oncology research in rare and aggressive cancers. AML represents a substantial clinical and economic burden, and progress depends on sustained investment, rigorous clinical trial oversight, and regulatory pathways that enable innovation. Event-driven survival studies such as REGAL also underscore the need for adaptive policy frameworks that accommodate longer survival trends without compromising statistical standards or patient safety.
In summary, SELLAS’ update on the Phase 3 REGAL trial marks a critical step toward the final evaluation of galinpepimut-S in AML, reinforcing confidence in the study’s conduct and design. With the trial approaching its predefined event threshold and remaining fully blinded, the company is positioned for a pivotal data readout that could reshape maintenance therapy options in a challenging leukemia setting. As the oncology community awaits unblinding and final analysis, REGAL stands as a high-stakes clinical program at the intersection of science, regulation, and patient need.
Source: SELLAS press release
